Skip to main content

Table 2 Patients’s status at the end of the study according to ESMO-ESGO-ESTRO modified risk assessment (ESMO 2015)

From: New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer

ESMO 2015 risk group Status of patients at the end of the study (n = 163)
Alive (no evidence of disease) Disease progression Cancer-related death Non cancer related death Total
1 27 (20.8%) 1 (8.33%) 0 0 28 (17.2%)
2 30 (23.1%) 0 0 1 (100%) 31 (19.0%)
3 11 (8.4%) 0 2 (10%) 0 13 (8.0%)
4 57 (43.8%) 7 (58.33%) 11 (55%) 0 75 (46.0%)
5 5 (3.9%) 4 (33.33) 5 (25%) 0 14 (8.6%)
6 0 0 2 (10%) 0 2 (1.2%)
Total 130 (100%) 12 (100%) 20 (100%) 1 (100%) 163 (100%)